Jim Simons Amylyx Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 396,200 shares of AMLX stock, worth $6.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

396,200

Previous 515,100 23.08%

Holding current value

$6.06 Million

Previous $1.82 Million 39.28%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$3.31 - $6.5 $393,559 - $772,850	-118,900 Reduced 23.08%	396,200 $2.54 Million
Q1 2025 May 14, 2025	BUY	$3.0 - $4.15 $152,100 - $210,405	50,700 Added 10.92%	515,100 $1.82 Million
Q4 2024 Feb 13, 2025	BUY	$2.94 - $7.03 $566,244 - $1.35 Million	192,600 Added 70.86%	464,400 $1.75 Million
Q3 2024 Nov 13, 2024	SELL	$1.65 - $3.24 $890,485 - $1.75 Million	-539,688 Reduced 66.51%	271,800 $880,000
Q2 2024 Aug 09, 2024	BUY	$1.62 - $2.71 $173,158 - $289,666	106,888 Added 15.17%	811,488 $1.54 Million
Q1 2024 May 13, 2024	BUY	$2.71 - $19.57 $1.72 Million - $12.4 Million	633,312 Added 888.39%	704,600 $2 Million
Q4 2023 Feb 13, 2024	SELL	$12.07 - $18.46 $951,260 - $1.45 Million	-78,812 Reduced 52.51%	71,288 $1.05 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $2.71 Million - $3.52 Million	150,100 New	150,100 $2.75 Million
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $5.3 Million - $7 Million	178,300 New	178,300 $6.59 Million
Q2 2022 Aug 12, 2022	SELL	$6.85 - $19.93 $1 Million - $2.92 Million	-146,400 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $1.88 Million - $4.82 Million	146,400 New	146,400 $1.88 Million

Others Institutions Holding AMLX

# of Institutions

149

Shares Held

75.8M

Call Options Held

212K

Put Options Held

40.6K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $895M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account